Amprologix, a University of Plymouth spinout company, has raised £740,000 through to accelerate development of its novel antibiotics to combat antimicrobial-resistant diseases.
[ARTICLE]
Research published earlier in 2025
Link to Article: Studies shows new class of antibiotic is effective in tackling MRSA
Link text
Open this link in a new tab
"> Research published earlier in 2025 showed a daily dose of epidermicin NI01, the lead candidate developed by the company, is as effective at treating wound infections - including those caused by Methicillin-resistant Staphylococcus aureus (MRSA) - as the current standard of care.
The results were achieved through a robust skin MRSA infection model, with the new funds to be used to complete pre-clinical development of epidermicin NI01 and support Phase I human clinical trials for therapy of wound infections.
In particular, there are plans to advance tests exploring whether the compound can be incorporated within gel-type therapies that can be applied to the skin.
Amprologix was founded to commercialise the pioneering research of Professor of Medical Microbiology
[STAFFMEMBER]
"> Professor Mathew Upton, a world-leading expert in antimicrobial resistance (AMR) and lead of the University's Antibiotic Resistant Pathogens Research Group.
It is also in the early stages of developing a novel antibiotic for Clostridioides difficile (C. difficile) - MRSA and C. difficile cause infections that can be difficult to treat and new therapies are urgently needed.
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
